JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

133.13

-0.58%↓

Home・Akciju saraksts・Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

83.76 2.32

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

81.28

Max

84.29

Galvenie mērījumi
By Trading Economics
Ienākumi	-252M -129M
Pārdošana	-295M 157M
Peļņas marža	-82.062
Darbinieki	1,069
EBITDA	-254M -103M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+16.09% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 18. febr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	1.5B 13B
Iepriekšējā atvēršanas cena	81.44
Iepriekšējā slēgšanas cena	83.76

Ziņu noskaņojums

By Acuity

80%

20%

325 / 352 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Neutral Evidence

29.78 / 33.645 Atbalsts un pretestība

Ionis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 28. janv. 23:51 UTC

Peļņas

Correction to Samsung Fourth-Quarter Net Profit Article

2026. g. 28. janv. 23:49 UTC

Karstas akcijas

Stocks to Watch: Meta, IBM, Las Vegas Sands, Whirlpool

2026. g. 28. janv. 23:19 UTC

Peļņas

Samsung's Fourth-Quarter Net Profit Beats Consensus

2026. g. 28. janv. 22:43 UTC

Peļņas

Waste Management Logs Higher 4Q Profit as Revenue Rises

2026. g. 29. janv. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

Diller's Overture Came Before Warner Unveiled Split Plans, Source Says -- WSJ

2026. g. 29. janv. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

Warner Says CNN Wasn't and Isn't for Sale -- WSJ

2026. g. 29. janv. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

Barry Diller Told Warner Bros. Discovery He Is Interested in Buying CNN -- WSJ

2026. g. 29. janv. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

Barry Diller Approached Warner Bros. Discovery Last Year About Buying CNN, Sources Say -- WSJ

2026. g. 28. janv. 23:49 UTC

Tirgus saruna

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

2026. g. 28. janv. 23:30 UTC

Tirgus saruna

Tesla to Use Car Factory for Robot Aims -- Market Talk

2026. g. 28. janv. 23:28 UTC

Peļņas

Microsoft's Earnings Surge, Elevated by Cloud Business -- 3rd Update

2026. g. 28. janv. 23:26 UTC

Peļņas

Meta Reports Record Sales, Massive Spending Hike on AI Buildout -- 2nd Update

2026. g. 28. janv. 23:21 UTC

Peļņas

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

2026. g. 28. janv. 23:18 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

2026. g. 28. janv. 22:58 UTC

Peļņas

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

2026. g. 28. janv. 22:48 UTC

Tirgus saruna

Woodside Energy Has Form With Conservative Production Guidance -- Market Talk

2026. g. 28. janv. 22:45 UTC

Peļņas

Samsung Electronics 2025 Net KRW45.207T Vs. Net KRW34.451T >005930.SE

2026. g. 28. janv. 22:44 UTC

Peļņas

Samsung Electronics 2025 Oper Pft KRW43.601T Vs. Pft KRW32.726T >005930.SE

2026. g. 28. janv. 22:43 UTC

Peļņas

Samsung Electronics 2025 Rev KRW333.606T Vs. KRW300.871T >005930.SE

2026. g. 28. janv. 22:41 UTC

Peļņas

Karstas akcijas

Earnings in Focus Wednesday: Microsoft, Tesla, Meta, Starbucks -- WSJ

2026. g. 28. janv. 22:41 UTC

Tirgus saruna

Rising AUD Typically Sees Australian Stocks Outperform -- Market Talk

2026. g. 28. janv. 22:41 UTC

Peļņas

Meta Stock Rises on Strong Earnings. Expenses Are Mounting. -- Barrons.com

2026. g. 28. janv. 22:40 UTC

Peļņas

Samsung Electronics 4Q Net Profit Beat FactSet-Compiled Consensus

2026. g. 28. janv. 22:39 UTC

Peļņas

Samsung Electronics 4Q Net KRW19.642T Vs. Net KRW7.754T >005930.SE

2026. g. 28. janv. 22:38 UTC

Peļņas

Samsung Electronics 4Q Oper Pft KRW20.074T Vs. Pft KRW6.493T >005930.SE

2026. g. 28. janv. 22:37 UTC

Peļņas

Samsung Electronics 4Q Rev KRW93.837T Vs. KRW75.788T >005930.SE

2026. g. 28. janv. 22:35 UTC

Peļņas

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

2026. g. 28. janv. 22:26 UTC

Tirgus saruna

Peļņas

Meta's Rising CapEx is Fueled by High Pay for AI Workers -- Market Talk

2026. g. 28. janv. 22:20 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 28. janv. 22:20 UTC

Tirgus saruna

Woodside Energy's Oil Assets Blamed for Guidance Miss -- Market Talk

Salīdzinājums

Cenas izmaiņa

Ionis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

16.09% augšup

Prognoze 12 mēnešiem

Vidējais 95.36 USD 16.09%

Augstākais 110 USD

Zemākais 77 USD

Pamatojoties uz 13 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Ionis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

13 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 13 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Ionis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

29.78 / 33.645Atbalsts un pretestība

The bullish and bearish events are balanced.

All events are bullish.

All events are bearish.

Noskaņojums

By Acuity

325 / 352 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.